Serina Therapeutics Inc. has reported its financial results for the first quarter ended March 31, 2025. The company recorded a net loss of $4.8 million for the quarter, which is a significant improvement compared to the net loss of $15.0 million reported for the same period in 2024. The company did not report material revenues for both the current and previous year's first quarter. Cash and cash equivalents stood at $4.3 million as of March 31, 2025. Serina Therapeutics projects these funds, along with an additional $5.0 million received from a securities purchase agreement in April 2025, to sustain operations through the third quarter of 2025. In terms of business highlights, Serina Therapeutics is on track to dose the first patient in its Phase 1b clinical trial of SER-252 for advanced Parkinson's disease in the fourth quarter of 2025. The company has strengthened its financial position through recent financing activities and has expanded its Board of Directors with two seasoned biotech leaders. Additionally, Serina presented new data on its POZ Platform at the 4th LNP Formulation & Process Development Summit 2025, showing that its POZ-lipid did not trigger an immune response in rats, a discovery that could lead to safer and more effective formulations for gene therapy and RNA-based medicines.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.